Collaboration - October 16, 2015
Nextera collaborates with Johnson & Johnson
Norwegian Nextera has entered into a research agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Nextera is a biotechnology company focused on developing novel and highly disease-specific immunotherapies for autoimmune diseases, cancer and chronic infections. Under terms of the agreement, Nextera will, with use of its unique technology platform, […]
Collaboration - September 8, 2015
AMRA in collaboration with Pfizer
The Swedish MedTech company AMRA has entered into an international collaboration with Pfizer. The companies will investigate the relationship between fat and muscle distribution in the body and metabolic health, including risk factors for conditions such as obesity and diabetes. The collaboration will assess fat and muscle measurements from magnetic resonance images in up to 7,000 […]
Collaboration - August 24, 2015
AZ, Peregrine to collaborate
AstraZeneca today announced that it has entered into a clinical trial collaboration with Peregrine Pharmaceuticals. The companies will evaluate the safety and efficacy of Peregrine’s investigational phosphatidylserine (PS)-signalling pathway inhibitor, bavituximab, in combination with AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, durvalumab (MEDI4736). The planned Phase I/Ib trial will evaluate the safety and efficacy of bavituximab in […]
Collaboration - August 10, 2015
MedImmune in strategic collaboration with Inovio Pharmaceuticals
MedImmune, AstraZeneca’s global biologics research and development arm, has entered into a license agreement and collaboration with Inovio Pharmaceuticals, a biotechnology company developing DNA-based immunotherapies for cancer and infectious diseases. Under the agreement, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which […]
Collaboration - August 6, 2015
Sprint Bioscience enters into collaboration with Bayer HealthCare
Sprint Bioscience AB and Bayer HealthCare have entered into a collaboration and license agreement for the research, development, and commercialization of oncological drug candidates. Under the agreement, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer. Subsequently, Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics […]
Collaboration - July 7, 2015
Astra Forms New Partnerships
AstraZeneca is involved in two new projects that focus on heart disease and respiratory illness. The company is partnering with the Montreal Heart Institute, which will search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes. AstraZeneca also has reached a new deal with Abbott Laboratories for a diagnostic […]
